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Abstract 
Background: There is a spectacular rise in the global prevalence of type 2 diabetes mellitus (T2DM) due to the 
worldwide obesity epidemic. However, a significant proportion of T2DM patients are non-obese and they also have 
an increased risk of cardiovascular diseases. As the Goto-Kakizaki (GK) rat is a well-known model of non-obese T2DM, 
the goal of this study was to investigate the effect of non-obese T2DM on cardiac alterations of the transcriptome in 
GK rats.
Methods: Fasting blood glucose, serum insulin and cholesterol levels were measured at 7, 11, and 15 weeks of age 
in male GK and control rats. Oral glucose tolerance test and pancreatic insulin level measurements were performed 
at 11 weeks of age. At week 15, total RNA was isolated from the myocardium and assayed by rat oligonucleotide 
microarray for 41,012 genes, and then expression of selected genes was confirmed by qRT-PCR. Gene ontology and 
protein–protein network analyses were performed to demonstrate potentially characteristic gene alterations and key 
genes in non-obese T2DM.
Results: Fasting blood glucose, serum insulin and cholesterol levels were significantly increased, glucose tolerance 
and insulin sensitivity were significantly impaired in GK rats as compared to controls. In hearts of GK rats, 204 genes 
showed significant up-regulation and 303 genes showed down-regulation as compared to controls according to 
microarray analysis. Genes with significantly altered expression in the heart due to non-obese T2DM includes func-
tional clusters of metabolism (e.g. Cyp2e1, Akr1b10), signal transduction (e.g. Dpp4, Stat3), receptors and ion channels 
(e.g. Sln, Chrng), membrane and structural proteins (e.g. Tnni1, Mylk2, Col8a1, Adam33), cell growth and differentia-
tion (e.g. Gpc3, Jund), immune response (e.g. C3, C4a), and others (e.g. Lrp8, Msln, Klkc1, Epn3). Gene ontology analysis 
revealed several significantly enriched functional inter-relationships between genes influenced by non-obese T2DM. 
Protein–protein interaction analysis demonstrated that Stat is a potential key gene influenced by non-obese T2DM.
Conclusions: Non-obese T2DM alters cardiac gene expression profile. The altered genes may be involved in the 
development of cardiac pathologies and could be potential therapeutic targets in non-obese T2DM.
Keywords: Spontaneous diabetes mellitus, Inherited diabetes mellitus, Non-obese type 2 diabetes mellitus, 
Myocardium, DNA microarray, GO, String, Insulin resistance
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Background
Diabetes mellitus is a heterogeneous chronic metabolic 
disorder characterized by hyperglycemia as a common 
feature resulting from impaired insulin secretion, insulin 
resistance, or both [1]. In 2014, the global prevalence of 
diabetes mellitus (DM) was estimated to be 9  % among 
adults according to WHO data [2]. The total number of 
people suffering from DM is projected to almost triple 
from 190 million to 552 million by 2030 [3, 4]. T2DM 
accounts for more than 90 % of all diabetes cases and its 
incidence is continuously rising worldwide [1, 5, 6]. The 
major cause for this phenomenon is the so-called obesity 
epidemic due to physical inactivity and increased con-
sumption of energy-rich food [7]. Nevertheless, it is often 
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neglected that around 20  % of T2DM patients are non-
obese in Europe and Asia [7–10]. The non-obese T2DM 
phenotype is characterized by a more pronounced reduc-
tion in insulin secretion and less severe insulin resist-
ance as compared to obese T2DM patients [7]. The risk 
of T2DM in non-obese individuals is considered to be 
mostly influenced by polygenic inheritance and prenatal 
environment [7].
It is well known that diabetic patients have an 
increased risk of developing a number of co-morbid-
ities including cardiovascular diseases (CVD). It has 
been reported that T2DM patients have a two to four-
fold increased risk of CVD in general [7, 11, 12]. Obe-
sity is recognized as an independent risk factor for 
both T2DM and CVD [7, 13]. Interestingly, it has been 
reported that non-obese T2DM patients also have 
a high risk of CVD similarly to that of obese T2DM 
patients [7, 11, 14]. Indeed, CVD are estimated to be 
responsible for more than 50 % of deaths among T2DM 
population [15].
One of the major pathologies of the aforementioned 
CVD is diabetic cardiomyopathy (DCM) [15, 16]. DCM 
is defined as left ventricular (LV) diastolic and/or sys-
tolic dysfunction with hypertrophy and fibrosis in the 
absence of preceding hypertension, coronary artery dis-
ease and valvular or congenital heart disease [15–17]. 
Although DCM is a distinct clinical entity, it is also a 
part of the diabetic atherosclerosis process [18]. DCM 
might be independent of the coexistence of arterial 
hypertension, coronary artery disease or other macro-
vascular complications [18]. DCM is characterized by 
the development of myocardial damage, reactive hyper-
trophy and fibrosis, structural and functional changes of 
the small coronary vessels, and cardiac autonomic neu-
ropathy [18]. These alterations make the diabetic heart 
more susceptible to ischemia and subsequent remodel-
ling [18–20].
We have previously shown that cardiac gene expression 
pattern is significantly altered in obese ZDF rats, a model 
of T2DM and metabolic syndrome [21], and in strepto-
zotocin-induced T1DM rats [22] at the transcript level. 
The effect of non-obese T2DM on gene expression pat-
tern in various tissue types has been investigated in a few 
studies. Pancreatic islets [23, 24], liver [25], skeletal mus-
cle [26], adipose tissue [27], hippocampus and prefron-
tal cortex [28] obtained from the well-known non-obese 
T2DM model Goto-Kakizaki (GK) rat showed altered 
gene expression pattern as compared to controls. Sur-
prisingly, whole transcriptomic analysis in the heart of 
GK rats has not been performed previously. Therefore, in 
the present study, our aim was to investigate the effect of 
non-obese T2DM on cardiac alterations of the transcrip-
tome in GK rats.
Methods
Ethics approval
This investigation conforms to the National Institutes 
of Health Guide for the Care and Use of Laboratory 
Animals (NIH Pub. No. 85–23, Revised 1996) and was 
approved by the Animal Research Ethics Committee of 
the University of Szeged.
Animal model of non‑obese T2DM
Male Goto-Kakizaki rats and their age-matched male 
Wistar controls were obtained from Charles River 
Laboratories at the age of 6  weeks and were housed 
at 22  ±  2  °C with a 12:12-h light–dark cycle. The rats 
received standard rat chow and water ad  libitum for 
9  weeks after their arrival. The GK rat is a recognized 
model of inherited type 2 diabetes mellitus [29]. This 
spontaneously diabetic rat strain was developed by selec-
tive breading of Wistar rats with the highest normal 
blood glucose levels in response to oral glucose toler-
ance test [30, 31]. GK rats develop a non-obese and mild 
hyperglycemic phenotype at week 4–5 accompanied by a 
metabolic state of glucose intolerance and later periph-
eral insulin resistance [29, 32] which develops to a hyper-
glycemic insulin-deficient state with aging [29, 32–34]. 
The metabolic features manifested in this animal model 
are in many ways similar to the pathogenesis of inher-
ited spontaneous T2DM in humans [29, 32]. However, 
hyperglycemia and glucose intolerance developed in GK 
rats are not associated with the development of obesity 
or hypertension [1]. The adult GK rat of T2DM has been 
shown to develop cardiovascular complications includ-
ing left ventricular hypertrophy, fibrosis, as well as dias-
tolic and/or systolic dysfunction [1, 20, 35, 36]. Therefore, 
the GK rat is an applicable model for investigation of the 
consequences of non-obese T2DM in the heart.
Experimental setup
Body weight, serum glucose, insulin, cholesterol levels 
and homeostasis model assessment-estimated insulin 
resistance (HOMA-IR) were determined at 7, 11 and 
15 weeks of age in order to monitor the basic parameters 
of glucose and lipid metabolism and insulin resistance 
in GK and control rats (Figs. 1, 2, 3). Oral glucose toler-
ance test (OGTT) was performed at week 15 to further 
characterize glucose homeostasis of GK and control rats 
(Fig. 2). At 15 weeks of age, rats were anaesthetized using 
pentobarbital sodium (Euthasol, 50  mg/kg, Produlab 
Pharma b.v., Raamsdonksveer, The Netherlands). Hearts 
and pancreata were isolated, and then hearts were per-
fused according to Langendorff as described earlier [21, 
37]. After 5 min perfusion ventricular tissue was frozen 
and stored at −80  °C until gene expression analysis by 
DNA microarray and qRT-PCR techniques.
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Serum glucose level measurements and OGTT
As described previously, rats were fasted overnight (12 h) 
prior to serum glucose level measurements and OGTTs 
(weeks 7, 11 and 15) to verify the development of hyper-
glycemia and glucose-intolerance as diagnostic crite-
ria of diabetes mellitus [21, 22, 36]. Blood samples were 
collected from the saphenous vein. Blood glucose levels 
were measured using AccuCheck blood glucose moni-
toring systems (Roche Diagnostics Corporation, USA, 
Indianapolis) [21, 22, 38]. In case of OGTT, after the 
measurement of baseline glucose concentrations, 1.5  g/
kg body weight glucose was administered per os via gav-
age and blood glucose levels were checked 30, 60 and 
120 min later [21, 22, 38]. Area under the curve values for 
OGTT was also calculated.
Measurement of serum and pancreatic insulin levels
Serum and pancreatic insulin levels were measured 
by an enzyme-linked immunosorbent assay (Merco-
dia, Ultrasensitive Rat Insulin ELISA) as described 
previously [21, 22, 38]. Blood samples were collected 
from the saphenous vein at weeks 7, 11 and 15. At 
week 15, during OGTT blood was collected at 0, 30 
and 120 min for serum insulin level measurements. 
Blood samples were centrifuged (4500 rpm for 10 min 
at 4  °C) and kept at −20  °C until the assay was per-
formed. At week 15, pancreata were removed, trimmed 
free of adipose tissue and weighed. Pancreata were 
homogenized in 6  mL cold acidified-ethanol (0.7  M 
HCl: ethanol, 1:3 v/v) with an Ultraturrax homog-
enizer and were kept at 4  °C for 24  h. Then pancreas 
homogenates were centrifuged (900g for 15  min at 
4  °C), and the supernatants were stored at 4  °C. The 
pellet was extracted again with 3 mL acidified ethanol 
for 24  h at 4  °C. The supernatant obtained after cen-
trifugation was pooled with the previous one and kept 
at −20 °C until assayed. Insulin ELISA was carried out 
according to the instructions of the manufacturer from 
either sera or homogenized pancreatic tissue samples 
of GK and control rats.
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Fig. 1 Fasting blood glucose, serum insulin and cholesterol levels. Fasting blood glucose (a), serum insulin (b) and cholesterol (c) levels as well as 
HOMA-IR index (d) at weeks 7, 11 and 15 in both control and GK rats. Values are mean ± SEM, n = 7–9, *p < 0.05 vs. control within the same time 
point, #p < 0.05 vs. week 7 values
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HOMA‑IR index
To estimate insulin resistance in GK or control rats the 
widely used HOMA-IR index was calculated [21, 39] by 
multiplying fasting serum insulin (μg/mL) with fasting 
blood glucose (mmol/L), then dividing by the constant 
22.5, i.e. HOMA-IR =  (fasting serum insulin concentra-
tion × fasting blood glucose concentration)/22.5.
Measurement of serum cholesterol levels
In order to follow up the development of hypercholester-
olemia which is a risk factor of cardiovascular diseases, 
serum cholesterol levels were measured at weeks 7, 11 
and 15 using a test kit (Diagnosticum Zrt., Budapest, 
Hungary) as described previously [21, 40, 41].
RNA preparation and DNA microarray analysis
Total RNA was isolated from heart samples with Qia-
gen miRNeasy Mini Kit according to the manufacturer’s 
protocol (Qiagen, Hilden, Germany) as described pre-
viously [22]. On-column DNase digestion was carried 
out with the RNase-Free DNase Set (Qiagen GmbH). 
RNA concentration was measured by NanoDrop 1000 
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Fig. 2 Blood glucose and insulin levels during OGTT and pancreatic insulin content. Blood glucose (a) and serum insulin (b) levels during OGTT, 
OGTT AUC (c) and pancreatic insulin (d) content at week 15 in both control and GK rats. Solid line control; dashed line GK. Values are mean ± SEM, 
n = 7–9, *p < 0.05
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Fig. 3 Body weight, heart weight and coronary flow. Body weight 
(a), heart weight (b), heart weight to body weight ratio (c) and 
coronary flow (d) at week 15 in both control and GK rats. Values are 
mean ± SEM, n = 7–9, *p < 0.05
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Spectrophotometer (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) and RNA integrity was determined 
by an Agilent 2100 Bioanalyzer System (Agilent Technol-
ogies Inc., Santa Clara, CA, USA). Samples with an RNA 
integrity number (RIN) above 8.0 were used for further 
analysis. RNA was stored at −80 °C until use.
Total RNA (1000 ng) was labelled and amplified using 
the QuickAmp Labelling Kit according to the instruc-
tions of the manufacturer. Labelled RNA was purified 
and hybridized to Agilent Whole Rat Genome 4 × 44 K 
array slides, according to the manufacturer’s protocol. 
After washing, array scanning and feature extraction was 
performed with default scenario by Agilent DNA Micro-
array Scanner and Feature Extraction Software 9.5.
Messenger RNA (mRNA) expression profiling by qRT‑PCR
In order to validate gene expression changes obtained 
by DNA microarray, qRT-PCR was performed with 
gene-specific primers. Total RNA (1  µg) was reverse 
transcribed using High-Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher Scientific, Waltham, MA 
US). Quantitative RT-PCR was performed using TaqMan 
Array 96 Well Fast Plate  3 ×  32 (Thermo Fisher Scien-
tific, Waltham, MA US) according to the manufacturer’s 
instructions on a 7900HT Fast Real-Time PCR System. 
Each well of the TaqMan Array Plate contained 5 μL of 
Taqman Fast Universal Master Mix (2X) no AmpErase® 
UNG, 1 μL cDNA (50 ng/μL) and 4 μL distilled water in 
a final reaction volume of 10 μL per well. Then qPCR was 
performed with the following protocol: 50 cycles of 95 °C 
for 15 s and 60  °C for 1 min. The fluorescence intensity 
was detected after each amplification step. Melting tem-
perature analysis was done after each reaction to check 
the quality of the products. Primers were designed using 
the online TaqMan® Assays custom plating service of the 
manufacturer. Relative expression ratios were calculated 
as normalized ratios to rat glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), hypoxanthine phosphoribosyl-
transferase (HPRT) and ribosomal protein S18 (RPS18) 
housekeeping genes. A non-template control sample was 
used for each primer to check primer-dimer formation. 
Normalized signal levels for each mRNA were calculated 
using comparative cycle threshold method (delta–delta 
Ct method). Fold change refers to 2−ΔΔCt (in the case 
of up-regulated genes) and −(1/2−ΔΔCt) (in the case of 
down-regulated genes).
Gene ontology (GO) analysis
By using DNA microarrays for transcriptional profiling 
a large number of genes can be analyzed simultaneously 
[21, 42], however, the resulting data do not give direct 
information about possible biological interaction of the 
differentially expressed genes. GO analysis is a suitable 
method for integration genes with pathways and biologi-
cal interaction networks to detect coordinated changes in 
functionally related genes [21, 42]. GO analysis was per-
formed using GO pathway analysis using the open access 
software DAVID bioinformatics system and database 
(Database for Annotation, Visualization and Integrated 
Discovery, http://www.david.abcc.ncifcrf.gov website) 
[21, 42]. The differentially expressed genes were submit-
ted to DAVID bioinformatics system and database to 
reveal significantly enriched biological functions/path-
ways [21, 42].
Protein–protein interaction analysis
Gene expression networks are of great biological inter-
est since co-expressed genes could be (1) controlled by 
the same transcriptional regulatory program, (2) func-
tionally related, or (3) members of the same pathway or 
protein complex [43]. In order to further characterize 
the connections of significantly altered genes obtained 
by DNA microarray, protein–protein network analysis 
was performed by STRING10 based on two types of evi-
dence: experimental (protein–protein interaction data-
bases) and text-mining (abstracts of scientific literature). 
STRING (http://www.string-db.org/), is an online acces-
sible database of known and predicted protein–protein 
interactions. Protein–protein interactions from STRING 
10 were collected for the construction of differential pro-
tein interaction network among the genes whose expres-
sions were significantly different in hearts of GK rats. The 
differently expressed genes were mapped to the String 
database and then known and predicted associations 
were scored and integrated. Combined-score  >  0.4 was 
the threshold. Differently expressed genes were visual-
ized after KMEANS clustering. Finally, interaction net-
work was constructed by integrating these relationships.
Statistical analysis
Statistical analysis was performed by using Sigmaplot 
12.0 for Windows (Systat Software Inc). All values are 
presented as mean ± SEM. Repeated measures Two-Way 
ANOVA was used to determine the effect of T2DM and 
the age on FBG, serum insulin and cholesterol levels as 
well as glucose levels during OGTT. After ANOVA, all 
pairwise multiple comparison procedures with Holm-
Šídák post hoc tests were used as multiple range tests. 
Two sample t test was used to determine the effect of 
T2DM on OGTT AUC, pancreatic insulin concentration, 
body weight, heart weight, heart weight/body weight 
ratio and coronary flow. P < 0.05 was accepted as a sta-
tistically significant difference. In the microarray experi-
ments, biological and technical replica tests were carried 
out to gain raw data for statistical analysis. Altogether 4 
individual parallel gene activity comparisons were done 
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between the two groups. Both in the microarray and qRT-
PCR experiments, a two-sample t test was used and the p 
value was determined to find significant gene expression 
changes. In the microarray experiments, a corrected p 
value was determined for each gene to control the false 
discovery rate using the Benjamini and Hochberg mul-
tiple testing correction protocol. Gene expression ratios 
with p value of  <0.05 and log2 ratio of  <  −1.00 or log2 
ratio of >1.00 (~2.0-fold were considered as repression or 
overexpression respectively in gene activity.
Results
Metabolic characterization of non‑obese T2DM
In order to verify the development of T2DM in male GK 
rats, concentrations of several serum metabolites were 
measured at weeks 7, 11 and 15 (Fig. 1). GK rats showed 
a significantly elevated FBG level at all time points as 
compared to controls (Fig. 1a). Interestingly, blood glu-
cose level in GK rats were significantly lower at week 11 
as compared to week 7 or week 15 blood glucose val-
ues (Fig. 1a). Parallel with hyperglycemia, serum insulin 
levels were significantly increased in GK rats compared 
to Wistar controls at week 7 and more profoundly at 
week 11 showing the presence of hyperinsulinemia in 
GK animals (Fig.  1b). However, there was no signifi-
cant difference between serum insulin levels measured 
in GK and control rats at week 15, since serum insu-
lin concentration in GK rats significantly decreased by 
week 15 as compared to insulin level measured at week 
11 indicating beta-cell damage in GK rats (Fig.  1b). 
HOMA-IR was significantly increased at weeks 7 and 11 
in GK rats when compared to controls showing insulin 
resistance in GK animals (Fig. 1d). In contrast, increase 
of HOMA-IR did not reach the level of statistical sig-
nificance at week 15 in GK animals (Fig.  1d). Serum 
cholesterol levels were significantly higher in GK rats as 
compared to control ones throughout the study dura-
tion representing hypercholesterolemia (Fig. 1c). OGTT 
was performed at week 15 in order to verify the devel-
opment of impaired glucose tolerance in GK rats. Glu-
cose levels during OGTT were markedly increased in 
GK rats in every time point of blood glucose measure-
ments (Fig.  2a). Area under the curve (AUC) of blood 
glucose levels during OGTT was significantly increased 
in GK rats representing impaired glucose tolerance 
(Fig.  2c). In addition, serum insulin level in GK rats 
during OGTT was significantly lower 30 min after glu-
cose loading and became markedly increased 120  min 
after glucose administration indicating impaired insu-
lin secretion (Fig.  2b). Interestingly, pancreatic insulin 
levels were 25 % lower in GK rats compared to control 
ones, however, the values were not significantly differ-
ent between the two groups (Fig. 2d).
Body weight, heart weight and coronary flow
Body weight was significantly decreased at week 15 in GK 
rats proving a non-obese phenotype of T2DM in GK rats 
(Fig. 3a). Heart weight and heart weight to body weight 
ratio were significantly increased at week 15 in GK rats 
suggesting the development of cardiac hypertrophy in 
response to chronic T2DM (Fig. 3b, c). Interestingly, cor-
onary flow was significantly increased at week 15 in GK 
rats as compared to control hearts (Fig. 3d).
Gene expression profile and qRT‑PCR
Among the 41,012 genes surveyed (Additional file  1: 
Table  S1), 507 genes whose expression was  >  ~2.0-fold 
up- or down-regulated in hearts of GK rats relative to 
levels of control rats showed significant change in expres-
sion. According to our results, 204 genes showed up-
regulation (Additional file  2: Table  S2) and 303 genes 
showed down-regulation in hearts of GK rats (Additional 
file 2: Table S3). Moreover, 138 genes showed more than 
threefold change of expression in hearts of GK rats as 
compared to the levels of control rats. Among these 138 
genes, 50 genes were significantly up-regulated (Table 1) 
and 88 genes were significantly down-regulated (Table 2) 
in GK rat hearts. The expression change of selected 28 
genes was validated by qRT-PCR (Table 3), 19 of these 28 
genes have been confirmed by qRT-PCR (Table 3).  
Gene ontology analysis
In order to further determine the biological significance 
and functional classification of differentially expressed 
genes due to non-obese T2DM, GO analysis was per-
formed (Table 4) [21]. GO analysis is suitable for identi-
fying significantly enriched GO terms related to multiple 
genes and for discovering enriched functionally related 
gene groups. A single gene can belong to different cat-
egories. Out of the 507 genes significantly altered by non-
obese T2DM in our present study, 277 genes with known 
function were submitted to GO analysis and 115 were 
clustered into different categories. The rest of the 507 
genes were either unknown expressed sequence tags or 
unrecognized by the GO analysis database (Table 4). The 
115 analyzed genes were classified into five main catego-
ries such as (1) biological regulation, (2) metabolic pro-
cess, (3) immune system process, (4) biological adhesion, 
and (5) rhythmic process (Table 4).
Protein–protein interaction analysis
To better understand the relationships between the 
functionally related gene groups analyzed by GO, we 
examined protein–protein interactions between protein 
products of all 507 genes showing significant difference 
in gene expression (Fig.  4). Here, Stat3 seems to have 
a major networking group affecting multiple top GO 
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Table 1 Up-regulated genes (>3.0-fold up-regulation)
Gene function Description (gene symbol) Acc. no. AVE log2 SD (LOG) P value (Corr) Fold change SD
Metabolism Abhydrolase domain containing 
17C (Abhd17c)
NM_001100736 2.79 0.39 0.00 6.96 1.72
Alcohol dehydrogenase 1 (class 
I) (Adh1)
NM_019286 2.43 0.99 0.00 5.38 2.78
Retinol saturase (all trans retinol 
13,14 reductase) (Retsat)
NM_145084 2.17 1.14 0.01 4.50 3.61
Diacylglycerol kinase, beta (Dgkb) NM_019304 2.07 0.34 0.00 4.21 0.82
Kallikrein 1-related peptidase C3 
(Klk1c3)
NM_001271315 1.92 0.45 0.00 3.79 1.07
Aldo–keto reductase family 1, 
member B10 (aldose reductase) 
(Akr1b10)
NM_001013084 1.91 0.44 0.00 3.76 1.05
Adenosine monophosphate 
deaminase 1 (Ampd1)
NM_138876 1.61 0.71 0.00 3.06 1.56
Signal transduction, regulation of 
transcription
Phospholipase A2, group VII 
(platelet-activating factor acetyl-
hydrolase, plasma) (Pla2g7)
NM_001009353 2.23 0.29 0.00 4.68 0.88
Protein tyrosine phosphatase, 
non-receptor type 13 (Ptpn13)
NM_001100789 2.13 1.06 0.00 4.38 2.18
Ephrin A2 (Efna2) NM_001168670 1.77 0.31 0.00 3.41 0.60
Crystallin, mu (Crym) NM_053955 1.76 0.39 0.00 3.38 0.78
Cd47 molecule (Cd47) NM_019195 1.74 0.26 0.00 3.34 0.51
Calsyntenin 2 (Clstn2) NM_134377 1.63 0.65 0.00 3.09 1.41
Ring finger protein 187 (Rnf187) NM_001164264 1.61 0.34 0.00 3.06 0.63
Receptors, ion channels Potassium voltage-gated channel, 
Isk-related family, member 1 
(Kcne1)
NM_012973 2.72 0.82 0.00 6.57 4.07
ATPase, H+ transporting, lysoso-
mal V1 subunit G2 (Atp6v1g2)
NM_212490 2.53 0.60 0.00 5.77 2.02
Cholinergic receptor, nicotinic, 
alpha 7 (neuronal) (Chrna7)
S53987 1.79 0.31 0.00 3.45 0.63
ATPase, Ca++ transporting, 
plasma membrane 2 (Atp2b2)
NM_012508 1.71 0.50 0.00 3.27 0.91
Membrane proteins Peroxisomal membrane protein 4 
(Pxmp4)
NM_172223 2.52 0.21 0.00 5.73 0.74
Cell growth and differentiation Transcription elongation factor A 
(SII)-like 7 (Tceal7)
NM_001109401 1.86 0.84 0.00 3.63 1.88
Jun D proto-oncogene (Jund) NM_138875 1.71 0.29 0.00 3.28 0.60
Immune response RT1 class Ib, locus T18 (RT1-T18) NM_001002821 2.31 0.77 0.00 4.95 2.21
2′-5′ oligoadenylate synthetase 1A 
(Oas1a)
NM_138913 1.98 0.86 0.00 3.94 2.50
Transport ATPase, Ca++ transporting, 
plasma membrane 2 (Atp2b2)
NM_012508 1.78 0.41 0.00 3.44 0.77
Solute carrier family 16 (monocar-
boxylate transporter), member 
7 (Slc16a7)
NM_017302 1.64 0.38 0.00 3.11 0.69
Others Guanylate binding protein 1, 
interferon-inducible (gbp1)
XM_006224278 4.80 0.49 0.00 27.84 8.96
Uncharacterized LOC102549588 XR_362031 4.69 0.54 0.00 25.85 8.31
Twin-arginine translocation path-
way signal
4.52 0.58 0.00 23.01 9.81
TL0ADA29YA08 mRNA sequence FQ222105 3.27 0.42 0.00 9.64 2.34
Similar to ribosomal protein L6 
(LOC366145)
XM_345411 2.94 0.59 0.00 7.70 3.03
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pathways in non-obese T2DM. Moreover, there are pro-
teins interconnected with each other in smaller network-
ing groups including networks of (1) Sdc1; (2) Cyp2e1 
and (3) Tef proteins (Fig.  4) affecting the top GO path-
ways as well (Table 4).
Discussion
In the present study, our aim was to investigate how car-
diac gene expression pattern is influenced by non-obese 
T2DM. Here we show several characteristics of non-
obese T2DM in 15  weeks old male GK rats including 
decreased body weight, fasting hyperglycemia, hyper-
cholesterolemia, insulin resistance, and impaired glucose 
tolerance. Moreover, we show increased heart weight and 
heart weight/body weight ratio in GK rats indicating car-
diac hypertrophy. We also demonstrate that non-obese 
T2DM influences cardiac gene expression pattern by 
altering transcript levels of several genes. We identified 
507 genes which were differentially expressed in the myo-
cardium of GK rats compared to Wistar controls.
The spontaneously diabetic GK rat is a well character-
ized and recognized model of non-obese type 2 diabetes 
mellitus. The abnormal glucose regulation in the GK rat 
develops in association both with impaired insulin secre-
tion and with insulin resistance as reviewed by Östenson 
and Movassat [29, 32]. At the onset of T2DM, there is a 
Table 1 continued
Gene function Description (gene symbol) Acc. no. AVE log2 SD (LOG) P value (Corr) Fold change SD
Mitochondrial ribosomal protein 
S10 (Mrps10)
NM_001008859 2.86 1.24 0.00 7.28 4.07
Cd300 molecule-like family mem-
ber G (Cd300lg)
XM_003750936 2.61 0.68 0.00 6.10 2.99
MRNA decapping enzyme 2.32 0.35 0.00 4.99 1.11
Transmembrane emp24 domain-
containing protein 5 precursor
2.14 0.28 0.00 4.41 0.72
Macrophage activation 2 like 
(Mpa2 l)
XM_006221662 2.10 1.05 0.00 4.30 3.00
Similar to interferon-inducible 
GTPase (RGD1309362)
NM_001024884 2.02 0.84 0.00 4.06 2.65
Myc-like oncogene, s-myc protein 
(Mycs)
NM_021837 2.00 0.80 0.00 4.00 1.64
Uncharacterized LOC102556738 XR_340771 1.96 0.44 0.00 3.89 1.10
Nuclear casein kinase and cyclin-
dependent kinase substrate 1 
(Nucks1)
XM_006249797 1.96 0.34 0.00 3.89 0.74
Transducin-like enhancer of split 
6 (E(sp1) homolog, Drosophila) 
(Tle6)
XM_006241027 1.95 0.43 0.00 3.87 1.10
Transmembrane protein 132C 
(Tmem132c)
XM_002724836 1.91 0.45 0.00 3.75 1.09
CWC25 spliceosome-associated 
protein homolog (S. cerevisiae) 
(Cwc25)
NM_001108295 1.82 0.76 0.00 3.52 1.65
Contactin associated protein-like 2 
(Cntnap2)
XM_006236412 1.79 0.39 0.00 3.47 0.84
Anaphase promoting complex 
subunit 10 (Anapc10)
XM_006255406 1.77 1.29 0.03 3.41 4.41
Deoxycytidine triphosphate 
deaminase
1.73 0.35 0.00 3.32 0.74
Hypothetical protein LOC500028 NM_001047954 1.65 0.38 0.00 3.13 0.66
RNA binding motif protein 44 
(Rbm44)
XM_001066845 1.64 0.46 0.00 3.12 0.87
Trichorhinophalangeal syndrome 
I (Trps1)
XM_006241626 1.62 0.39 0.00 3.08 0.69
Excision repair cross-complement-
ing rodent repair deficiency, 
complementation group 8 
(Ercc8)
NM_001107650 1.60 0.27 0.00 3.03 0.49
Uncharacterized LOC100912569 XR_348427 1.59 0.82 0.01 3.02 1.80
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Table 2 Down-regulated genes (>3.0-fold down-regulation)
Gene function Description (gene symbol) Acc. no. AVE log2 SD (LOG) P value (Corr) Fold change SD
Metabolism Transglutaminase 1 (Tgm1) NM_031659 −1.98 0.55 0.0002 −3.93 1.87
CARBONIC anhydrase 6 (Car6) NM_001134841 −2.03 0.76 0.0002 −4.08 2.61
Phenazine biosynthesis-like protein domain 
containing 1 (Pbld1)
NM_138530 −2.14 0.68 0.0001 −4.41 2.60
Coproporphyrinogen oxidase (Cpox) NM_001037095 −2.32 0.45 0.0001 −4.98 2.06
Prolyl 4-hydroxylase, alpha polypeptide III 
(P4ha3)
XM_006229769 −2.36 0.38 0.0001 −5.13 1.68
Signal transduction, 
regulation of  
transcription
cAMP responsive element binding protein 5 
(Creb5)
XM_006236505 −1.62 0.52 0.0001 −3.07 1.26
Dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 3 (Dyrk3)
NM_001024767 −1.74 0.65 0.0006 −3.35 1.95
Hypermethylated in cancer 1 (Hic1) NM_001107021 −1.83 0.70 0.0019 −3.55 2.10
Rho guanine nucleotide exchange factor 
(GEF) 5 (Arhgef5)
XM_006224892 −1.96 0.47 0.0001 −3.89 1.45
Thyroid hormone responsive (Thrsp) NM_012703 −2.28 0.98 0.0020 −4.86 5.18
Cellular retinoic acid binding protein 2 
(Crabp2)
NM_017244 −2.32 0.50 0.0001 −4.98 2.42
A kinase (PRKA) anchor protein 3 (Akap3) NM_001005557 −2.68 0.35 0.0000 −6.39 1.90
Uroplakin 1B (Upk1b) NM_001024253 −3.69 0.69 0.0001 −12.89 7.94
Receptors, ion  
channels
Interleukin 22 receptor, alpha 2 (Il22ra2) NM_001003404 −1.62 0.93 0.0064 −3.07 2.78
Neurotrophic tyrosine kinase, receptor, type 3 
(Ntrk3), transcript variant 3
NM_019248 −1.64 0.45 0.0005 −3.12 1.18
Adrenoceptor alpha 1D (Adra1d) NM_024483 −1.69 0.37 0.0007 −3.23 1.09
Lysophosphatidic acid receptor 1 (Lpar1) NM_053936 −1.83 0.51 0.0000 −3.55 1.50
Prostaglandin F receptor (Ptgfr) NM_013115 −1.87 0.44 0.0000 −3.65 1.40
Solute carrier family 4 (anion exchanger), 
member 1 (Slc4a1)
NM_012651 −2.39 0.22 0.0000 −5.23 0.94
Sarcolipin (Sln) NM_001013247 −3.00 1.41 0.0028 −8.03 15.41
ATPase, H + transporting, lysosomal accessory 
protein 1-like (Atp6ap1 l)
NM_001191843 −3.59 0.31 0.0000 −12.06 3.25
Membrane proteins Sarcolipin (Sln) CK841541 −2.51 1.08 0.0019 −5.68 7.12
Structural protein,  
cell adhesion
Collagen, type V, alpha 3 (Col5a3) NM_021760 −1.78 0.59 0.0001 −3.43 1.46
Contactin associated protein 1 (Cntnap1) NM_032061 −2.03 0.34 0.0000 −4.09 1.11
Myosin binding protein H-like (Mybphl) NM_001014042 −2.82 1.17 0.0011 −7.08 8.55
Myosin, light chain 7, regulatory (Myl7) NM_001106017 −3.37 1.66 0.0030 −10.34 20.29
Mesothelin (Msln) NM_031658 −4.46 1.44 0.0010 −22.03 31.18
Cell growth and  
differentiation
Ret proto-oncogene (Ret), transcript variant 1 NM_012643 −1.64 0.44 0.0000 −3.11 1.15
Endothelial cell-specific molecule 1 (Esm1) NM_022604 −2.28 0.39 0.0000 −4.85 1.57
Neuronatin (Nnat), transcript variant 1 NM_053601 −2.34 1.34 0.0119 −5.06 10.47
Endothelial cell-specific molecule 1 (Esm1) NM_022604 −2.36 0.40 0.0000 −5.13 1.64
Epiphycan (Epyc) NM_001108088 −2.36 1.37 0.0083 −5.14 7.64
Cyclin G1 (Ccng1) NM_012923 −3.36 0.21 0.0000 −10.29 1.82
Tripartite motif-containing 16 (Trim16) NM_001135033 −6.33 0.41 0.0000 −80.63 28.07
Immune response Regenerating islet-derived 3 beta (Reg3b) NM_053289 −1.81 1.34 0.0300 −3.52 5.83
Inducible T-cell co-stimulator ligand (Icoslg) XM_006223832 −1.92 0.37 0.0000 −3.79 1.16
Complement component 4A (Rodgers blood 
group) (C4a)
NM_031504 −2.25 0.75 0.0002 −4.77 3.07
Chemokine (C-X-C motif ) ligand 13 (Cxcl13) NM_001017496 −2.48 0.78 0.0003 −5.57 4.38
Similar to immunoglobulin superfamily, mem-
ber 7 (RGD1559482),
NM_001168285 −2.54 0.43 0.0000 −5.83 2.19
CD1d1 molecule (Cd1d1) NM_017079 −2.64 0.53 0.0000 −6.21 2.67
Chymase 1, mast cell (Cma1) NM_013092 −3.95 0.45 0.0000 −15.40 6.26
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Table 2 continued
Gene function Description (gene symbol) Acc. no. AVE log2 SD (LOG) P value (Corr) Fold change SD
Transport Retinol binding protein 4, plasma (Rbp4) NM_013162 −2.09 1.20 0.0131 −4.27 7.22
Hormones Inhibin alpha (Inha) NM_012590 −1.79 0.56 0.0020 −3.45 1.80
Others Protein Arhgef5 (Source:UniProtKB/
TrEMBL;Acc:E9PT59)
XM_006224892 −1.62 0.54 0.0002 −3.07 1.33
Hypothetical protein LOC100302372 
(LOC100302372)
NM_001162897 −1.63 0.57 0.0004 −3.10 1.69
(F344/Crj)rearranged mRNA for T-cell receptor 
gamma chain (1483 bp)
Z27087 −1.65 0.71 0.0045 −3.13 1.94
Similar to RIKEN cDNA 1700001E04 
(LOC367428), mRNA (XM_346135)
XM_346135 −1.65 0.25 0.0000 −3.14 0.68
BTB (POZ) domain containing 9 (Btbd9) XM_006256185 −1.66 0.30 0.0000 −3.15 0.73
Q99NG8_RAT (Q99NG8) T:G mismatch thy-
mine glycosylase
−1.67 0.44 0.0001 −3.17 1.24
Hypothetical protein LOC689316 (LOC689316) XR_086061 −1.68 0.39 0.0000 −3.21 1.02
Uroplakin 3B-like (Upk3bl) NM_001109020 −1.69 0.37 0.0013 −3.22 1.04
NEUU_MOUSE (Q9QXK8) Neuromedin U-23 
precursor (NmU-23)
−1.71 0.43 0.0000 −3.28 1.10
Ripply transcriptional repressor 2 (Ripply2) XM_001064780 −1.73 0.44 0.0000 −3.31 1.22
Uncharacterized LOC100912446 
(LOC100912446)
FQ221838 −1.73 0.64 0.0005 −3.33 1.76
Similar to TP53-regulating kinase (p53-related 
protein kinase) (Nori-2) (LOC685619)
XM_002729250 −1.75 0.32 0.0000 −3.37 0.84
Erythrocyte membrane protein band 4.1-like 
3 (Epb41l3)
NM_053927 −1.77 0.90 0.0057 −3.41 2.69
Uncharacterized LOC102556259 
(LOC102556259)
XR_355327 −1.77 0.38 0.0001 −3.42 1.22
EF-hand domain family, member D1 (Efhd1) NM_001109310 −1.81 0.46 0.0000 −3.50 1.45
Zinc finger and BTB domain containing 20 
(Zbtb20)
XM_006248302 −1.87 0.48 0.0000 −3.67 1.69
Suppressor of glucose, autophagy associated 
1 (Soga1)
XM_001067659 −1.89 0.66 0.0001 −3.72 2.23
Protein RGD1562667 XM_221091 −1.91 0.45 0.0000 −3.75 1.49
Uncharacterized protein (Source:UniProtKB/
TrEMBL;Acc:F1LSJ2) (ENSRNOT00000035259)
XM_001061015 −1.93 0.61 0.0001 −3.80 2.07
Uncharacterized LOC102546664 
(LOC102546664)
XR_342060 −1.95 0.18 0.0000 −3.87 0.58
Protein Rsf1 (Source:UniProtKB/
TrEMBL;Acc:D3ZGQ8)
XM_218939 −1.95 1.05 0.0109 −3.87 2.89
Nucleosome assembly protein 1-like 5 
(Nap1l5)
NM_001044293 −1.97 1.04 0.0039 −3.92 3.86
Methyltransferase like 2B (Mettl2b) NM_001108839 −2.07 0.40 0.0000 −4.20 1.36
Similar to immunoreceptor Ly49si3 
(LOC690097)
XM_003753951 −2.19 0.50 0.0001 −4.55 2.20
Neuronal PAS domain protein 2 (Npas2) NM_001108214 −2.23 0.47 0.0000 −4.69 1.73
FM089532 etnofat cDNA clone etno-
fatP0014D18 5′, mRNA sequence
FM089532 −2.40 0.36 0.0001 −5.28 1.54
Chordin-like 1 (Chrdl1) NM_199502 −2.46 0.27 0.0000 −5.51 1.30
Uncharacterized LOC102557390 
(LOC102557390)
XR_348511 −2.54 0.48 0.0000 −5.82 2.30
Q7TQ12_RAT (Q7TQ12) Aa1114 −2.62 0.32 0.0000 −6.14 1.69
TL0ACA45YL24 mRNA sequence FQ215947 −2.65 0.48 0.0000 −6.27 2.81
Aryl hydrocarbon receptor nuclear transloca-
tor-like (Arntl)
NM_024362 −2.75 0.54 0.0000 −6.75 2.85
Similar to RIKEN cDNA 1500015O10 
(RGD1305645)
NM_001271051 −2.84 0.88 0.0003 −7.17 7.06
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compensatory attempt of the beta cells to release more 
insulin to defeat insulin resistance. Later this mecha-
nism is insufficient to maintain blood glucose level within 
a physiological range and finally leads to the functional 
exhaustion of the surviving beta cells. These stages in the 
GK model could be also observed in our present study. 
Blood glucose levels were significantly increased in GK 
rats at weeks 7, 11 and 15 as compared to controls and 
there was a statistically significant difference in blood glu-
cose levels in GK rats between the different time points. 
Blood glucose level in GK rats were significantly lower at 
week 11 as compared to week 7 or week 15 blood glucose 
values. Moreover, serum insulin level was significantly 
increased at week 11 in GK rats as compared to week 7 
values. The significantly higher serum insulin level at 
week 11 could explain the lower blood glucose level at 
week 11 as compared to week 7 blood glucose values. 
Serum insulin levels and HOMA-IR were significantly 
increased at week 7 and 11 showing increasing insulin 
resistance and compensatory hyperinsulinemia. At week 
15, there was no significant difference in serum insulin 
level between GK and control animals. However, pan-
creatic insulin content of GK rats was slightly decreased 
suggesting the functional exhaustion of pancreatic beta 
cells. Probably this is the reason why HOMA-IR failed 
to reach the level of statistical significance in GK rats 
compared to controls at this time point. Nevertheless, 
this is not a sign of spontaneous improvement of insulin 
resistance in GK rats in our present study. These results 
are in accordance with literature data showing that beta 
cell mass and insulin production continuously decreases 
from birth to adulthood in GK rats due to chronic islet 
inflammation, angiopathy, fibrosis and defective beta cell 
neogenesis [32].
Surprisingly, only a few studies were performed previ-
ously using the qPCR technique to investigate the gene 
expression changes playing a role in the development of 
left ventricular hypertrophy and structural remodeling 
[20, 35, 44], excitation–contraction coupling [45, 46], and 
lipotoxicity [10] in the hearts of GK rats. Thus, our study 
is the first to describe overall alterations in the cardiac 
transcriptome in male GK rats. In our present study, the 
significantly altered genes can be classified into different 
clusters (e.g. metabolism, stress response, signal transduc-
tion, regulation of transcription, receptors, ion channels, 
membrane and structural proteins, cell growth and differ-
entiation, immune response, transport, hormones, etc.). 
Moreover, some other genes without any definite function 
in the myocardium were also changed in response to DM. 
The majority of these genes have not been related to non-
obese T2DM yet, and therefore, characterization of the 
functional effects of these genes on the heart in non-obese 
T2DM is suggested in future mechanistic studies.
Genes related to metabolic alterations in T2DM
In our present study, several genes related to metabo-
lism were found to be affected in the hearts of GK rats 
as compared to controls. A group of these altered genes 
Table 2 continued
Gene function Description (gene symbol) Acc. no. AVE log2 SD (LOG) P value (Corr) Fold change SD
Uncharacterized LOC100911508 
(LOC100911508)
XR_145872 −2.86 0.30 0.0000 −7.25 1.86
TL0ACA40YB18 mRNA sequence. FQ216879 −2.99 1.21 0.0012 −7.94 9.21
Family with sequence similarity 216, member 
B (Fam216b)
XM_003751515 −3.04 0.89 0.0002 −8.25 6.41
SARCO_MOUSE (Q9CQD6) Sarcolipin, com-
plete (TC628765)
AW918768 −3.06 1.35 0.0020 −8.33 14.57
Endogenous retrovirus mRNA AY212271 −3.51 1.47 0.0015 −11.38 17.10
Uncharacterized LOC102552170 
(LOC102552170)
XM_006224493 −4.01 0.40 0.0000 −16.09 5.74
O89816_9GAMR (O89816) Envelope glyco-
protein
−4.04 0.99 0.0001 −16.49 15.56
Rat PRRHIS8 mRNA for ribosomal protein S8. 
(X56846)
X56846 −4.14 0.73 0.0000 −17.63 12.05
Elongator protein 3/MiaB/NifB −4.21 0.37 0.0000 −18.51 5.56
Endogenous retrovirus mRNA AY212271 −4.21 1.48 0.0006 −18.52 28.67
Similar to 60S ribosomal protein L19 
(LOC316856)
XM_229366 −4.46 0.84 0.0000 −22.05 16.63
Uncharacterized LOC102554872 
(LOC102554872)
XR_348916 −4.86 0.35 0.0000 −29.02 8.07
WDNM1 homolog (LOC360228) NM_001003706 −5.14 1.80 0.0013 −35.24 76.86
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is involved in cellular ketone metabolic process accord-
ing to GO and STRING protein–protein interaction 
analyses (e.g. down-regulation of cytochrome P450 
2E1, (Cyp2e1); cytochrome P450 2J4, (Cyp2j4); and up-
regulation of aldehyde dehydrogenase 1 family, mem-
ber A1, (Aldh1a1); alcohol dehydrogenase 1, (Adh1c); 
aldo–keto reductase family 1, member B10, (Akr1b10); 
aldo–keto reductase family 1, member, C12, (Akr1c12); 
etc.) (Fig. 4; Table 4). It has been shown that 60 day old 
GK rats developed increased ketone body production 
[47], however, there is no literature data available about 
ketone body metabolism in the heart of GK rats. The 
ketone body acetone can be converted in vivo to glucose 
via acetol and pyruvate, and the initial conversion to ace-
tol is catalyzed by Cyp2e1 [48]. It has been shown that 
Cyp2e1 knockout mice subjected to starvation to induce 
ketogenesis develop blood acetone levels much higher 
than those observed in wild-type mice [48]. In our pre-
sent study, the down-regulation of Cyp2e1 might be a 
possible cause of increased ketone body level in the myo-
cardium, however, up-regulation of other genes involved 
in ketone metabolic process including Aldh1a1; Adh1c; 
Akr1b10; and Akr1c12 may be an adaptive response in 
the myocardium to antagonize elevated ketone body 
levels. Moreover, Akr1b10 has been shown to be induc-
ible by hyperglycemia in peripheral blood mononuclear 
cells obtained from patients with diabetic nephropathy. It 
also could have potential downstream effect of reducing 
cellular retinoic acid level, which is a key molecule dur-
ing organogenesis as well as the development of diabetic 
Table 3 Confirmation by qRT-PCR
Gene symbol Gene name Acc. nr. DNA microarray qRT‑PCR Confirmed
AVE (log2) Fold change Fold change SEM
Adipoq Adiponectin, C1Q and collagen domain containing Rn00595250_m1 −4.99 −31.78 −23.64 0.02 Yes
Retn Resistin Rn00595224_m1 −4.74 −26.72 31.08 14.46 No
Atp1b4 ATPase, (Na+)/K+ transporting, beta 4 polypeptide Rn00584523_m1 −4.21 −18.51 −4.74 0.05 Yes
Car3 Carbonic anhydrase 3 Rn01461970_m1 −3.73 −13.27 −7.88 0.03 Yes
Cma1 Chymase 1, mast cell Rn00565319_m1 −3.11 −8.63 −5.12 0.02 Yes
Arntl Aryl hydrocarbon receptor nuclear translocator-like Rn00577590_m1 −2.75 −6.74 −2.95 0.03 Yes
Tgm1 Transglutaminase 1, K polypeptide Rn00581408_m1 −1.97 −3.92 −4.88 0.03 Yes
Nnat Neuronatin (Nnat), transcript variant 1 Rn00440480_m1 −1.87 −3.66 −4.2 0.02 Yes
Ddah1 Dimethylarginine dimethylaminohydrolase 1 Rn00574200_m1 −1.69 −3.23 −3.36 0.02 Yes
Ntrk3 Neurotrophic tyrosine kinase, receptor, type 3 Rn00570389_m1 −1.69 −3.23 −2.33 0.06 Yes
Stat3 Signal transducer and activator of transcription 3 Rn00562562_m1 −1.49 −2.81 1.36 0.08 No
Dpp4 Dipeptidylpeptidase 4 Rn00562910_m1 −1.35 −2.55 −2.11 0.03 Yes
Ephx2 Epoxide hydrolase 2, cytoplasmic Rn00576023_m1 −1.33 −2.51 −4.23 0.02 Yes
Gpc3 Glypican 3 Rn00516722_m1 −1.29 −2.45 −2.54 0.04 Yes
Fgf18 Fibroblast growth factor 18 Rn00433286_m1 −1.17 −2.25 −2.36 0.03 Yes
Tfpi Tissue factor pathway inhibitor (lipoprotein-associ-
ated coagulation inhibitor)
Rn00567935_m1 −1.10 −2.14 1.12 0.06 No
Gckr Glucokinase (hexokinase 4) regulator Rn00565467_m1 −0.98 −1.97 −2.09 0.05 N/A
Cdkn1a Cyclin-dependent kinase inhibitor 1A Rn00589996_m1 −0.93 −1.91 −1.34 0.04 N/A
Bat5 HLA-B associated transcript 5 Rn01525709_g1 0.96 1.95 −1.3 0.06 N/A
Sele Selectin E Rn00594072_m1 1.02 2.03 2.35 0.14 Yes
Dbp D site of albumin promoter (albumin D-box) bind-
ing protein
Rn00497539_m1 1.06 2.08 2.39 0.17 Yes
Abcg1 ATP-binding cassette, subfamily G (WHITE), mem-
ber 1
Rn00585262_m1 1.08 2.11 1.99 0.14 No
Cyr61 Cysteine-rich, angiogenic inducer, 61 Rn00580055_m1 1.14 2.20 1.58 0.12 No
Ephx1 Epoxide hydrolase 1, microsomal Rn00563349_m1 1.21 2.31 2.24 0.18 Yes
Prkce Protein kinase C, epsilon Rn01769089_m1 1.28 2.43 1.09 0.08 No
Nurp1 Nuclear protein, transcriptional regulator, 1 Rn00586046_m1 1.34 2.53 3.29 0.28 Yes
Slc16a7 Solute carrier family 16, member 7 (monocarbox-
ylic acid transporter 2)
Rn00568872_m1 1.77 3.41 3.21 0.19 Yes
Atp2b2 ATPase, C++ transporting, plasma membrane 2 Rn01425460_m1 1.88 3.68 3.78 0.21 Yes
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Table 4 Gene ontology analysis
Category Term Count % P value Gene symbol
GOTERM_BP_1 GO:0065007 ~ biological regulation 48 41.74 0.01 FGF18, PDIA2, GPBP1, C3, CRABP2, TRIM16, 
ZEB2, LPAR1, ESM1, SGMS1, CCNG1, CD1D1, 
ALDH1A1, ATP2B2, CD47, NPAS2, DGKB, 
ZFP90, CXCR6, JUND, PER2, TEF, CHRNA7, 
CNTNAP1, TRAF6, QSOX1,DDAH1, DPP4, 
DPT, CYR61, RET, NCF1, NUCKS1, ARHGEF5, 
PRKAB2, LOC501307, ARNTL, PTGFR, PRKCE, 
TMEM189, STAT3, FMN1, TRPS1, KLRE1, 
GNB3, EIF2AK2, ICOSLG, BARD1
GOTERM_BP_2 GO:0006950 ~ response to stress 16 13.91 0.04 NCF1, PDIA2, C3, SGMS1, CD1D1, STAT3, 
ALDH1A1, ERCC8, SDC1, PLOD2, CHRNA7, 
TRAF6, EIF2AK2, DDAH1, DPP4, BARD1
GOTERM_BP_2 GO:0050789 ~ regulation of biological 
process
45 39.13 0.02 FGF18, PDIA2, GPBP1, C3, TRIM16, ZEB2, 
LPAR1, ESM1, SGMS1, CD1D1, ALDH1A1, 
ATP2B2, CD47, NPAS2, DGKB, ZFP90, CXCR6, 
JUND, PER2, TEF, CHRNA7, CNTNAP1, TRAF6, 
QSOX1, DDAH1, DPP4, DPT, CYR61, RET, 
NCF1, NUCKS1, ARHGEF5, PRKAB2, ARNTL, 
PTGFR, PRKCE, TMEM189, STAT3, FMN1, 
TRPS1, KLRE1, GNB3, EIF2AK2, ICOSLG, 
BARD1
GOTERM_BP_2 GO:0048518 ~ positive regulation of biologi-
cal process
24 20.87 0.00 FGF18, C3, GPBP1, ZEB2, TRIM16, ARNTL, 
LPAR1, CD1D1, STAT3, FMN1, ALDH1A1, 
ATP2B2, CD47, NPAS2, JUND, KLRE1, TEF, 
CHRNA7, EIF2AK2, TRAF6, DDAH1, ICOSLG, 
CYR61, BARD1
GOTERM_BP_2 GO:0048646 ~ anatomical structure forma-
tion involved in morphogenesis
9 7.83 0.00 ALDH1A1, ATP2B2, FGF18, RET, RIPPLY2, ZEB2, 
TRAF6, DDAH1, CYR61
GOTERM_BP_2 GO:0009653 ~ anatomical structure morpho-
genesis
14 12.17 0.03 FMN1, ALDH1A1, ATP2B2, FGF18, SDC1, RET, 
EFNA2, CRABP2, RIPPLY2, ZEB2, TRAF6, 
DDAH1, STAT3, CYR61
GOTERM_BP_1 GO:0008152 ~ metabolic process 48 41.74 0.03 CYP2J4, OCLN, C3, CRABP2, TRIM50, TRIM16, 
LPAR1, SGMS1, ALDH1A1, ATP2B2, ERCC8, 
MCM8, ST6GALNAC3, PLOD2, ZFP90, CPOX, 
P4HA3, JUND, PER2, TEF, CHRNA7, TRAF6, 
QSOX1, DDAH1, DPP4, RET, NCF1, PRKAB2, 
LOC501307, ARNTL, CRYZ, TMEM189, 
LPCAT2, PRKCE, WEE1, STAT3, RPS7, OXSM, 
FMN1, TAF13, SLC16A7, AKR1B10, PLA2G7, 
CMA1, EIF2AK2, CAR6, PRPS2, BARD1
GOTERM_BP_2 GO:0044237 ~ cellular metabolic process 39 33.91 0.09 CYP2J4, OCLN, CRABP2, TRIM50, TRIM16, 
LPAR1, SGMS1, ALDH1A1, ATP2B2, ERCC8, 
MCM8, ST6GALNAC3, ZFP90, CPOX, JUND, 
PER2, TEF, CHRNA7, TRAF6, QSOX1, DDAH1, 
RET, NCF1, PRKAB2, LOC501307, ARNTL, 
TMEM189, PRKCE, LPCAT2, WEE1, STAT3, 
RPS7, OXSM, TAF13, SLC16A7, EIF2AK2, 
CAR6, PRPS2, BARD1
GOTERM_BP_3 GO:0034641 ~ cellular nitrogen compound metabolic 
process
19 16.52 0.09 OCLN, LOC501307, ARNTL, LPCAT2, STAT3, RPS7, ERCC8, 
ATP2B2, MCM8, TAF13, ZFP90, CPOX, JUND, TEF, PER2, 
CHRNA7, DDAH1, PRPS2, BARD1
GOTERM_BP_4 GO:0006575 ~ cellular amino acid derivative 
metabolic process
4 3.48 0.10 ATP2B2, OCLN, CHRNA7, LPCAT2
GOTERM_BP_3 GO:0010033 ~ response to organic substance 11 9.57 0.09 ALDH1A1, CYP2J4, SDC1, JUND, TRIM16, CHRNA7, 
GNB3, EIF2AK2, DDAH1, STAT3, CYR61
GOTERM_BP_4 GO:0014070 ~ response to organic cyclic sub-
stance
5 4.35 0.05 ALDH1A1, CYP2J4, JUND, CHRNA7, STAT3
GOTERM_BP_3 GO:0006629 ~ lipid metabolic process 9 7.83 0.08 ALDH1A1, CYP2J4, NCF1, CRABP2, PRKAB2, PLA2G7, 
SGMS1, LPCAT2, OXSM
GOTERM_BP_4 GO:0006720 ~ isoprenoid metabolic process 3 2.61 0.06 ALDH1A1, CYP2J4, CRABP2
GOTERM_BP_5 GO:0006720 ~ isoprenoid metabolic process 3 2.61 0.05 ALDH1A1, CYP2J4, CRABP2
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Table 4 continued
Category Term Count % P value Gene symbol
GOTERM_BP_5 GO:0001523 ~ retinoid metabolic process 3 2.61 0.02 ALDH1A1, CYP2J4, CRABP2
GOTERM_BP_4 GO:0042573 ~ retinoic acid metabolic process 2 1.74 0.10 ALDH1A1, CRABP2
GOTERM_BP_3 GO:0044255 ~ cellular lipid metabolic process 8 6.96 0.04 ALDH1A1, CYP2J4, NCF1, CRABP2, PRKAB2, SGMS1, 
LPCAT2, OXSM
GOTERM_BP_4 GO:0044255 ~ cellular lipid metabolic process 8 6.96 0.04 ALDH1A1, CYP2J4, NCF1, CRABP2, PRKAB2, SGMS1, 
LPCAT2, OXSM
GOTERM_BP_3 GO:0006082 ~ organic acid metabolic process 8 6.96 0.06 ALDH1A1, CYP2J4, SLC16A7, NCF1, CRABP2, PRKAB2, 
DDAH1, OXSM
GOTERM_BP_4 GO:0043436 ~ oxoacid metabolic process 8 6.96 0.06 ALDH1A1, CYP2J4, SLC16A7, NCF1, CRABP2, PRKAB2, 
DDAH1, OXSM
GOTERM_BP_5 GO:0019752 ~ carboxylic acid metabolic process 8 6.96 0.05 ALDH1A1, CYP2J4, SLC16A7, NCF1, CRABP2, PRKAB2, 
DDAH1, OXSM
GOTERM_BP_3 GO:0042180 ~ cellular ketone metabolic process 8 6.96 0.07 ALDH1A1, CYP2J4, SLC16A7, NCF1, CRABP2, PRKAB2, 
DDAH1, OXSM
GOTERM_BP_3 GO:0006721 ~ terpenoid metabolic process 3 2.61 0.02 ALDH1A1, CYP2J4, CRABP2
GOTERM_BP_4 GO:0016101 ~ diterpenoid metabolic process 3 2.61 0.02 ALDH1A1, CYP2J4, CRABP2
GOTERM_BP_5 GO:0006721 ~ terpenoid metabolic process 3 2.61 0.02 ALDH1A1, CYP2J4, CRABP2
GOTERM_BP_1 GO:0002376 ~ immune system process 10 8.70 0.05 CD47, NCF1, C3, RT1-T18, KLRE1, CHRNA7, 
TRAF6, CD1D1, DDAH1, DPP4
GOTERM_BP_2 GO:0045321 ~ leukocyte activation 5 4.35 0.06 KLRE1, CHRNA7, TRAF6, CD1D1, DPP4
GOTERM_BP_3 GO:0045321 ~ leukocyte activation 5 4.35 0.05 KLRE1, CHRNA7, TRAF6, CD1D1, DPP4
GOTERM_BP_4 GO:0046649 ~ lymphocyte activation 4 3.48 0.10 KLRE1, CHRNA7, CD1D1, DPP4
GOTERM_BP_2 GO:0006955 ~ immune response 7 6.09 0.06 CD47, NCF1, C3, RT1-T18, TRAF6, CD1D1, 
DDAH1
GOTERM_BP_2 GO:0002682 ~ regulation of immune system 
process
7 6.09 0.04 CD47, C3, KLRE1, TRAF6, CD1D1, DDAH1, DPP4
GOTERM_BP_3 GO:0050776 ~ regulation of immune response 6 5.22 0.02 C3, KLRE1, TRAF6, CD1D1, DDAH1, DPP4
GOTERM_BP_4 GO:0050776 ~ regulation of immune response 6 5.22 0.01 C3, KLRE1, TRAF6, CD1D1, DDAH1, DPP4
GOTERM_BP_5 GO:0002253 ~ activation of immune response 4 3.48 0.02 C3, KLRE1, TRAF6, DDAH1
GOTERM_BP_4 GO:0002697 ~ regulation of immune effector 
process
5 4.35 0.01 C3, KLRE1, TRAF6, CD1D1, DPP4
GOTERM_BP_5 GO:0002697 ~ regulation of immune effector 
process
5 4.35 0.00 C3, KLRE1, TRAF6, CD1D1, DPP4
GOTERM_BP_5 GO:0002706 ~ regulation of lymphocyte mediated 
immunity
5 4.35 0.00 C3, KLRE1, TRAF6, CD1D1, DPP4
GOTERM_BP_5 GO:0002703 ~ regulation of leukocyte mediated 
immunity
5 4.35 0.00 C3, KLRE1, TRAF6, CD1D1, DPP4
GOTERM_BP_4 GO:0002819 ~ regulation of adaptive immune 
response
4 3.48 0.01 C3, TRAF6, CD1D1, DPP4
GOTERM_BP_3 GO:0002682 ~ regulation of immune system process 7 6.09 0.04 CD47, C3, KLRE1, TRAF6, CD1D1, DDAH1, DPP4
GOTERM_BP_4 GO:0002684 ~ positive regulation of immune 
system process
6 5.22 0.02 CD47, C3, KLRE1, TRAF6, CD1D1, DDAH1
GOTERM_BP_2 GO:0002252 ~ immune effector process 4 3.48 0.05 CD47, NCF1, C3, DDAH1
GOTERM_BP_3 GO:0002252 ~ immune effector process 4 3.48 0.05 CD47, NCF1, C3, DDAH1
GOTERM_BP_4 GO:0006968 ~ cellular defense response 2 1.74 0.05 NCF1, DDAH1
GOTERM_BP_1 GO:0022610 ~ biological adhesion 7 6.09 0.09 CD47, SDC1, RET, CNTNAP1, COL5A3, BTBD9, 
CYR61
GOTERM_BP_2 GO:0007155 ~ cell adhesion 7 6.09 0.09 CD47, SDC1, RET, CNTNAP1, COL5A3, BTBD9, 
CYR61
GOTERM_BP_1 GO:0048511 ~ rhythmic process 7 6.09 0.00 ALDH1A1, NPAS2, JUND, PER2, TEF, CHRNA7, 
ARNTL
GOTERM_BP_2 GO:0007623 ~ circadian rhythm 4 3.48 0.01 NPAS2, JUND, PER2, ARNTL
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nephropathy [49]. In our present study, non-obese T2DM 
also influenced expression of genes related to epoxide 
metabolism (down-regulation of Epoxide hydrolase 2, 
cytoplasmic, (Ephx2); glutathione S-transferase alpha 2, 
(Gsta2) and up-regulation of Epoxide hydrolase 1, micro-
somal, (xenobiotic) (Ephx1) (Fig. 3). Epoxides are possi-
ble products of Cyp450 catalyzed oxidation of aromatic 
compounds which can lead to toxic, mutagenic or carci-
nogenic effects [50]. One possibility for their inactivation 
is the metabolism by epoxide hydrolases. In addition, 
glutathione-S-transferase catalyzed nucleophilic attack 
by glutathione may also lead to the inactivation of epox-
ides [50]. In our present study, Cyp2e1, Cyp2j4, Ephx2 
and Gsta2 were down-regulated, showing decreased 
activity of epoxide metabolism. Moreover, glutathione 
S-transferase is a well-known enzyme catalyzing the 
conjugation of reduced glutathione on a wide variety of 
substrates including reactive oxygen and nitrogen species 
Fig. 4 Protein–protein interaction networks. Predicted protein–protein interaction network of protein products of genes associated with non-
obese T2DM. The circle stands for genes and the line indicates the interactions among genes. The interior of the circle represents the structure of 
proteins. The thickness of the line indicates the grade of evidence of the different interactions among proteins
Page 16 of 21Sárközy et al. Cardiovasc Diabetol  (2016) 15:110 
[51, 52]. Our results suggest that down-regulation of the 
anti-oxidative gene Gsta2 may contribute to elevated 
myocardial oxidative/nitrative stress, a phenomenon 
that has been demonstrated in T2DM by several studies 
[53, 54]. Interestingly, we have found overexpression of 
glutathione S-transferase in the heart in streptozotocin-
induced DM in neonatal rats [22], metabolic syndrome 
[21] and cholesterol diet-induced hyperlipidaemia [55] in 
our previous studies. Moreover, polymorphism of Ephx2 
has been shown to be a possible risk factor for developing 
insulin resistance and T2DM [56]. In addition, polymor-
phisms of another gene, the cellular retinoic acid binding 
protein 2 (Crapb2, down-regulated in our present study) 
has been reported to be a genetic marker of metabolic 
syndrome [57] and hypercholesterolemia [58].
Genes related to diabetic cardiomyopathy
One of the major cardiovascular complications of DM is 
diabetic cardiomyopathy [59, 60], which is defined as left 
ventricular dysfunction with hypertrophy and fibrosis in 
the absence of hypertension, coronary artery disease and 
valvular or congenital heart disease [61]. The complex 
underlying molecular mechanisms of the above-men-
tioned functional and morphologic changes are not yet 
clear despite intensive investigations [59–61].
Structure elements
In our present study, we have shown altered expres-
sion of several genes playing a role in myocardial struc-
ture formation and potentially related to diabetic 
cardiomyopathy based on GO and STRING protein–pro-
tein interaction analyses. These altered genes include e.g. 
down-regulation of ADAM metallopeptidase domain 
33 (Adam33); collagen, type V, alpha 3, (Col5a3); syn-
decan 1, (Sdc1); glypican 3 (Gpc3); troponin I type 1 
(skeletal, slow) (Tnni1); myosin, light chain 7, regula-
tory (Myl7); myosin light chain kinase 2 (Mylk2) and up-
regulation of collagen, type VIII, alpha 1, (Col8a1); etc. 
(Fig. 4; Table 4). Adam33 is a member of the ADAM pro-
tein family encoding a disintegrin and metalloprotease 
(ADAM) domain 33. It plays a role in cell–cell and cell–
matrix interactions, including muscle development and 
neurogenesis and its polymorphism is associated with 
the development of T1DM [62]. Moreover, elevated type 
VIII collagen deposition in human diabetic nephropathy 
was demonstrated leading to the accumulation of extra-
cellular matrix and periglomerular and interstitial fibro-
sis. Another ECM component, collagen V, is expressed 
as α1(V)2 α2(V) heterotrimers, which regulate collagen 
fibril geometry and strength in several tissues includ-
ing the pancreas and skeletal muscle. Interestingly, skel-
etal muscle of Col5a3−/− mice was defective in glucose 
uptake and mobilization of intracellular GLUT4 glucose 
transporter to the plasma membrane in response to 
insulin thereby leading to a glucose intolerant, insulin-
resistant, and hyperglycemic phenotype [63]. Membrane 
proteoglycans Gpc3 and Sdc1 have not yet been dem-
onstrated to play a role in the development of diabetic 
cardiomyopathy, however, increased expression of the 
heparan sulfate proteoglycans Gpc1 and Sdc4 has been 
shown to lead to diastolic dysfunction in streptozotocin-
induced diabetic rats [64]. In addition, decreased expres-
sion of the genes playing a role in contractility including 
troponin I [65, 66], myosin light chain 7 [67] and myosin 
light chain kinase 2 [67] could lead to sarcomeric dys-
function and diabetic cardiomyopathy.
Receptors and ion channels
In our present study, several genes with receptor and/or 
ion channel function were found to be affected by non-
obese T2DM and these genes might play a role in the 
development of diabetic cardiomyopathy. These genes 
include e.g. down-regulation of adrenoceptor alpha 1d 
(Adra1d); cholinergic receptor, nicotinic, gamma (mus-
cle) (Chrng); cholinergic receptor, nicotinic, alpha 1 
(muscle) (Chrna1); sarcolipin (Sln) and up-regulation 
of cholinergic receptor, nicotinic, alpha 7 (neuronal) 
(Chrna7); etc. Down-regulation of Adra1d receptor sub-
type has been previously shown in cardiac hypertrophy 
[68] and in STZ-induced DM by our research group [22]. 
Autonomic dysfunction is a serious complication of dia-
betes and can lead to cardiovascular abnormalities. It 
could be triggered by advanced glycation end products 
and reactive oxygen species mediated inactivation of neu-
ronal nicotinic acetylcholine receptors, impairing synap-
tic transmission in sympathetic ganglia and resulting in 
autonomic failure [69]. Myocardial down-regulation of 
Chrng and Chrna1 demonstrated in our present study 
might be another factor of cardiac autonomic dysfunc-
tion in diabetes. Moreover, it has been demonstrated that 
nicotinic cholinergic receptor alpha 7 (Chrna7) null mice 
showed decreased baroreflex-mediated tachycardia [70]. 
Sarcolipin (Sln) is a key regulator of sarcoplasmic reticu-
lum Ca2+-ATPase (SERCA) and mediator of β-adrenergic 
responses [71]. It has been shown that Sln−/− mice are 
susceptible to develop atrial arrhythmias and interstitial 
fibrosis due to altered expression of genes encoding colla-
gen [71]. Ablation or mutation of Sln results in increased 
SERCA activity and Ca2+ load, causing abnormal intra-
cellular Ca2+ handling and atrial remodeling with dys-
function [71, 72].
Signal transduction, regulation of transcription 
and biological processes
A major cluster of significantly altered cardiac genes in 
response to non-obese T2DM was associated with signal 
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transduction, regulation of transcription and biological 
processes based on GO and STRING protein–protein 
interaction analyses (e.g. down-regulation of dipeptidyl-
peptidase 4 (Dpp4); signal transducer and activator of 
transcription 3 (acute-phase response factor) (Stat3); ret 
proto-oncogene transcript variant 1 (Ret); neurotrophic 
tyrosine kinase, receptor, type 2 (Ntrk2); neurotrophic 
tyrosine kinase, receptor, type 3 (Ntrk3) and up-reg-
ulation of Jun D proto-oncogene (Jund); etc.) (Fig.  4; 
Table 4). Dipeptidyl peptidase-4 is an integral membrane 
glycoprotein which cleaves N-terminal dipeptides from 
peptide molecules. The cleaved dipeptides are bioactive 
molecules regulating the cardiovascular system as well. 
Dpp4 inhibitors have been reported to be cardiopro-
tective in most of the preclinical and clinical studies in 
T2DM [73]. In contrast, some cardiovascular outcome 
studies revealed increased hospitalization rates for heart 
failure among a subset of DPP4 inhibitor-treated diabetic 
subjects [74]. Recently a preclinical study has reported 
that diabetic mice treated with Dpp4 inhibitor exhibited 
modest cardiac hypertrophy, impairment of cardiac func-
tion, and dysregulated expression of genes and proteins 
controlling inflammation and cardiac fibrosis [75]. In our 
present study, Dpp4 was down-regulated; therefore it 
does not seem to be a major and/or necessary regulator 
in the development of diabetic cardiomyopathy in non-
obese T2DM. The transcription factor Stat3 participates 
in a wide variety of physiological processes including pro-
liferation, apoptosis, and cardiac survival especially dur-
ing myocardial ischemia/reperfusion injury, however, its 
role is contradictory in these aforementioned processes 
[76]. Several studies have reported that cardiac Stat3 
and phospho-Stat3 expression were reduced in diabetes, 
which can lead to cardiac dysfunction [76–78]. How-
ever, other studies reported that cardiac Stat3 and phos-
pho-Stat3 expression were increased in diabetes leading 
to hypertrophy [79, 80]. Furthermore, it has been also 
reported that Stat3 deficient mice developed dilated car-
diomyopathy [76] and patients with dilated cardiomyopa-
thy had severely decreased myocardial Stat3 expression 
[81]. In the present study, Stat3 was down-regulated as 
assessed by microarray, however, qRT-PCR did not con-
firm these results in our hands. Expression of Stat3 might 
depend on the duration of DM and the stage of diabetic 
cardiomyopathy or heart failure. Moreover, there is no 
literature data available about Stat3 expression in hearts 
of GK rats; therefore we could not compare our results 
to others. Surprisingly, down-regulation of Tef and Ret as 
well as up-regulation of Jund has not been shown previ-
ously to play a role in the development of diabetic car-
diomyopathy. It has been reported that Ret-deficient 
mice exhibited a reduced volume of cardiac ganglia and 
cholinergic innervation of the ventricular conduction 
system [82]. JunD regulates genes involved in antioxi-
dant defense and hydrogen peroxide (H2O2) production, 
as well as angiogenesis by controlling VEGF transcrip-
tion [83]. Furthermore, an important function for JunD 
is to modulate insulin/insulin-like-growth factor 1 sign-
aling and longevity [83]. Moreover, down-regulation 
of Ntrk2 and Ntrk3 genes might also play a role in the 
development of diabetic cardiomyopathy. Interestingly, it 
has been reported that mice with disrupted Ntrk2 gene 
lacked a significant proportion of their intramyocardial 
blood vessels indicating that activation of the Ntrk2 gene 
was crucial for normal vascularization of the develop-
ing heart [84]. In addition, mutations of Ntrk3 gene have 
been shown in the development of human congenital 
heart diseases [85].
Genes related to immune and antimicrobial response
A major cluster of significantly altered cardiac genes in 
response to non-obese T2DM in GK rats was associated 
with immune and antimicrobial response based on GO 
and STRING protein–protein interaction analyses (e.g. 
complement component 3 (C3); complement component 
4a (C4a); chemokine (C–C motif ) ligand 12 (Ccl12); 
chemokine (C-X-C motif ) ligand 13 (Cxcl13); chemokine 
(C-X-C motif ) ligand 14 (Cxcl14); chymase 1, mast cell 
(Cma1) and up-regulation of chemochine (C-X-C motif ) 
receptor 6 (Cxcr6); killer cell lectin-like receptor, family 
E, member 1 (Klre1); etc.) which is in line with the well-
known increased susceptibility to infections in DM [86, 
87].
Novel genes previously not related to diabetic alterations 
in the heart
Many of the genes showing altered expression in diabetic 
hearts in the present study have not yet been related to 
any diabetic alterations in the heart (e.g. down-regulation 
of low density lipoprotein receptor-related protein 8, 
apolipoprotein E receptor (Lrp8) and mesothelin (Msln) 
and up-regulation of kallikrein 1-related peptidase C3 
(Klk1c3) and Epsin 3 (Epn3); etc.) (Table 4). Some other 
altered genes were not classified into specific functional 
clusters or indicated as yet uncharacterized, predicted 
genes and fragments (e.g. up-regulation of hydroxya-
cyl glutathione hydrolase-like and Similar to hepatic 
leukemia factor (LOC690286) or down-regulation of 
uncharacterized LOC102546816 and similar to protein 
C17orf72; etc.) (Table 4), the relevance of which should 
not be ignored.
Limitations
Our study is not without limitations. Insulin resistance 
was estimated in our study by determining HOMA-
IR rather than the gold standard hyperinsulinemic 
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euglycemic clamp technique. Nevertheless, the presence 
of insulin resistance in GK rats has been confirmed in 
several studies [88–91]. Although detailed morphological 
or histological analysis of GK hearts is lacking, our data 
including increased heart weight, heart weight to body 
weight ratio and coronary flow together with literature 
data suggest the development of LV hypertrophy in our 
model. Although our study does not specify which cell 
type (i.e. cardiomyocyte, fibroblast, smooth muscle cell, 
etc.) may be responsible for the observed alterations of 
cardiac gene expression due to DM, the contribution of 
cardiomyocytes is likely the most significant [92, 93]. In 
addition, it is unclear whether significantly altered gene 
expression changes at the mRNA level are further trans-
lated to changes in protein levels and if gene expression 
changes are causes or consequences of the development 
of diabetic cardiomyopathy, therefore, additional in-
depth mechanistic studies should be carried out.
Conclusions
In summary, we have found that 15 week old male GK rats 
develop non-obese T2DM and we have demonstrated for 
the first time that non-obese T2DM is associated with 
a profound modification of the cardiac transcriptome. 
Some of the genes showing altered expression in the 
hearts of GK rats have been implicated in non-obese 
T2DM previously by other techniques. Some of the 
genes showing altered expression in our present study in 
non-obese T2DM have been reported to be associated 
with cardiac alterations in obese T2DM or T1DM mod-
els. Many of the genes showing significant expressional 
alterations in GK rat hearts in the present study have not 
been associated with non-obese T2DM previously. We 
conclude that non-obese T2DM alters the gene expres-
sion pattern of the myocardium. These altered genes may 
be involved in the development of cardiac pathologies 
in the state of non-obese type 2 diabetes mellitus. Based 
on our exploratory results, future studies should be car-
ried out to investigate the precise role of specific genes in 
the development of cardiac consequences of non-obese 
T2DM to obtain deeper mechanistic insight.
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